Home/Pipeline/ACI-12589

ACI-12589

TDP-43 proteinopathies (e.g., ALS)

PreclinicalActive

Key Facts

Indication
TDP-43 proteinopathies (e.g., ALS)
Phase
Preclinical
Status
Active
Company

About AC Immune

AC Immune's mission is to diagnose, treat, and prevent neurodegenerative diseases through a precision medicine approach. The company has achieved significant validation through high-value partnerships with major pharmaceutical firms like Takeda, Janssen, and Lilly, and its pipeline features promising Phase 2 candidates in Alzheimer's and Parkinson's disease. Its strategy balances internal R&D of first- and best-in-class candidates with strategic collaborations that provide non-dilutive funding and de-risk development.

View full company profile